| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,105 |
2,644 |
$734K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,495 |
3,359 |
$729K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,277 |
647 |
$328K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,422 |
2,208 |
$230K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,002 |
1,414 |
$162K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,966 |
2,472 |
$154K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,291 |
983 |
$110K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
946 |
761 |
$100K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,358 |
503 |
$86K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,411 |
520 |
$81K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
879 |
786 |
$71K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,178 |
949 |
$64K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
964 |
754 |
$56K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
356 |
307 |
$49K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
522 |
494 |
$40K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
268 |
198 |
$33K |
| 80053 |
Comprehensive metabolic panel |
4,969 |
4,017 |
$30K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
642 |
616 |
$22K |
| 87631 |
|
165 |
159 |
$22K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,922 |
1,724 |
$21K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
618 |
476 |
$20K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,418 |
3,463 |
$18K |
| 71045 |
Radiologic examination, chest; single view |
2,995 |
2,132 |
$18K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
190 |
162 |
$16K |
| 70450 |
Computed tomography, head or brain; without contrast material |
451 |
332 |
$13K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
348 |
194 |
$12K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
391 |
315 |
$11K |
| 83605 |
|
1,601 |
1,251 |
$10K |
| 71046 |
Radiologic examination, chest; 2 views |
1,360 |
855 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
7,809 |
5,728 |
$10K |
| 86140 |
|
2,232 |
1,794 |
$8K |
| 83880 |
|
630 |
475 |
$7K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
68 |
67 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
109 |
96 |
$7K |
| 82553 |
|
887 |
685 |
$6K |
| 84484 |
|
975 |
745 |
$6K |
| 83690 |
|
1,041 |
900 |
$5K |
| 80306 |
|
449 |
399 |
$5K |
| 81025 |
|
695 |
637 |
$5K |
| 81000 |
|
1,733 |
1,505 |
$5K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
122 |
39 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
279 |
272 |
$4K |
| 85027 |
|
815 |
714 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
286 |
252 |
$4K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
39 |
37 |
$4K |
| 82550 |
|
951 |
734 |
$4K |
| 73630 |
|
490 |
373 |
$4K |
| 87040 |
|
450 |
392 |
$4K |
| 80061 |
Lipid panel |
432 |
415 |
$4K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
35 |
29 |
$3K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
102 |
38 |
$3K |
| 83021 |
|
301 |
290 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
626 |
532 |
$3K |
| 85610 |
|
1,285 |
975 |
$3K |
| 90461 |
|
346 |
196 |
$3K |
| 85730 |
|
766 |
649 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
489 |
372 |
$2K |
| 87088 |
|
339 |
312 |
$2K |
| 84145 |
|
147 |
116 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
699 |
589 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
624 |
531 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
413 |
394 |
$1K |
| 73610 |
|
162 |
127 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
744 |
597 |
$1K |
| 82803 |
|
84 |
67 |
$1K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
13 |
12 |
$962.97 |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
29 |
28 |
$933.25 |
| 73030 |
|
107 |
74 |
$805.49 |
| J2704 |
Injection, propofol, 10 mg |
46 |
38 |
$716.04 |
| 85379 |
|
84 |
77 |
$647.32 |
| 72100 |
|
50 |
41 |
$589.16 |
| 36600 |
|
31 |
25 |
$514.56 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
46 |
41 |
$489.72 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
12 |
12 |
$468.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
12 |
12 |
$468.00 |
| 73562 |
|
54 |
37 |
$450.02 |
| 84439 |
|
79 |
74 |
$416.57 |
| 90686 |
|
30 |
30 |
$394.05 |
| 73110 |
|
37 |
25 |
$350.50 |
| 81015 |
|
132 |
124 |
$345.76 |
| 76942 |
|
13 |
13 |
$315.04 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
100 |
81 |
$275.72 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
152 |
130 |
$258.03 |
| 86677 |
|
16 |
16 |
$225.68 |
| J7050 |
Infusion, normal saline solution, 250 cc |
75 |
38 |
$208.43 |
| 73130 |
|
26 |
24 |
$191.08 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14 |
14 |
$190.15 |
| 87070 |
|
17 |
17 |
$161.87 |
| 83735 |
|
62 |
52 |
$131.32 |
| 82150 |
|
16 |
15 |
$79.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
48 |
44 |
$78.85 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
14 |
13 |
$78.03 |
| 86308 |
|
12 |
12 |
$57.50 |
| A4215 |
Needle, sterile, any size, each |
12 |
12 |
$44.92 |
| 85652 |
|
25 |
24 |
$30.31 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
15 |
15 |
$3.08 |
| 90670 |
|
45 |
44 |
$0.41 |
| 90647 |
|
40 |
40 |
$0.39 |
| 90723 |
|
32 |
31 |
$0.28 |
| 90680 |
|
31 |
30 |
$0.27 |
| 90685 |
|
13 |
13 |
$0.13 |
| 90633 |
|
14 |
14 |
$0.13 |
| 91300 |
|
12 |
12 |
$0.00 |
| 96376 |
|
12 |
12 |
$0.00 |
| A9270 |
Non-covered item or service |
69 |
26 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
13 |
13 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
424 |
354 |
$-999.47 |